Developing RNA-targeting medicines to treat previously incurable diseases
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.
Rgenta Therapeutics Raises $52M in Series A Financing
CAMBRIDGE, Mass., Nov. 29, 2022 /PRNewswire/ — Rgenta Therapeutics Inc. announced today that it closed a $52 million Series A round led by AZ-CICC Healthcare Investment Fund with participation from all existing investors and new investors including Korean Investment Partners, Delos Capital. Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets. Read more …
Work with us
At Rgenta, our vision is aligned with one goal- to serve patients- by paving the way in precision medicine.
If you are bold, see the possibilities in front of you and strive to be impactful, we want to meet you!